All In Biotech

Drug Trial Radar · NCT07614958

Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days

A Double-Blind, Randomized, Comparative Study of Obicetrapib and Bempedoic Acid on Top of Maximally Tolerated Lipid-Lowering Therapy in Patients With Dyslipidemia at High to Very High Cardiovascular Risk

Last checked: Nov 19, 2026Latest source record: Jun 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 426 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

426

Planned (sponsor's estimate)

Start

May 6, 2026

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Sponsor type
Industry
Collaborators
Medpace, Inc.
First posted
May 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3, randomized, double-blind, active-controlled study evaluates the efficacy and safety of obicetrapib (OBI) compared to bempedoic acid (BPA) in participants with dyslipidemia at high or very high cardiovascular risk. Participants must have elevated low density lipoprotein cholesterol (LDL-C) levels despite receiving maximally tolerated lipid lowering therapy. The primary objective is to compare the LDL-C lowering effect of OBI (a CETP inhibitor) against BPA at 12 weeks

Conditions

  • Mixed Dyslipidemia
  • Hypercholesterolaemia

Interventions

  • Obicetrapib 10 mg/Bempedoic Acid PlaceboDrug

    Orally, Once Daily

  • Bempedoic Acid 180mg/Placebo ObicetrapibDrug

    Orally, Once Daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary efficacy endpoint is the percentage change from baseline to Day 84 in LDL-C in the OBI group compared to the BPA group.Time frame: 84 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • FutureMeds North Tees

    Stockton-on-Tees, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.